FGF19 and fatty liver disease: DHA-CHO-VE supplementation improved severe hepatic steatosis (ranging 5-50%, p=0.001); ALT and fasting glucose levels.DHA-CHO-VE supplementation did not influence bile acid levels, while increased intestinal FGF19 compared to placebo.